CellaVision AB (publ) (STO: CEVI)

Market Cap	6.28B
Revenue (ttm)	726.40M
Net Income (ttm)	145.06M
Shares Out	23.85M
EPS (ttm)	6.08
PE Ratio	43.33
Forward PE	34.14
Dividend	2.25 (0.85%)
Ex-Dividend Date	May 6, 2024

Volume	5,275
Open	261.00
Previous Close	260.50
Day's Range	261.00 - 269.00
52-Week Range	120.00 - 283.50
Beta	1.12
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1994
• Employees: 221
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CEVI

Financial Performance

In 2023, CellaVision AB's revenue was 677.29 million, an increase of 5.94% compared to the previous year's 639.34 million. Earnings were 130.31 million, an increase of 10.12%.